LMR Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-9,000
| Closed | -$2.43M | – | 821 |
|
|
2025
Q1 | $2.43M | Sell |
9,000
-2,901
| -24% | -$783K | 0.02% | 324 |
|
|
2024
Q4 | $2.8M | Sell |
11,901
-55,588
| -82% | -$13.1M | 0.02% | 294 |
|
|
2024
Q3 | $18.6M | Buy |
67,489
+58,518
| +652% | +$16.1M | 0.15% | 71 |
|
|
2024
Q2 | $2.18M | Sell |
8,971
-62,400
| -87% | -$15.2M | 0.02% | 248 |
|
|
2024
Q1 | $10.7M | Buy |
71,371
+43,171
| +153% | +$6.45M | 0.11% | 100 |
|
|
2023
Q4 | $5.4M | Sell |
28,200
-39,524
| -58% | -$7.57M | 0.06% | 170 |
|
|
2023
Q3 | $12M | Buy |
67,724
+33,029
| +95% | +$5.85M | 0.13% | 107 |
|
|
2023
Q2 | $6.59M | Buy |
34,695
+13,551
| +64% | +$2.57M | 0.07% | 153 |
|
|
2023
Q1 | $4.24M | Buy |
+21,144
| New | +$4.24M | 0.07% | 285 |
|
|
2022
Q4 | – | Sell |
-4,107
| Closed | -$822K | – | 1087 |
|
|
2022
Q3 | $822K | Sell |
4,107
-134,266
| -97% | -$26.9M | 0.02% | 771 |
|
|
2022
Q2 | $20.2M | Buy |
138,373
+46,259
| +50% | +$6.75M | 0.34% | 53 |
|
|
2022
Q1 | $15M | Buy |
92,114
+69,886
| +314% | +$11.4M | 0.17% | 117 |
|
|
2021
Q4 | $3.77M | Buy |
+22,228
| New | +$3.77M | 0.04% | 292 |
|
|
2017
Q4 | – | Sell |
-50,588
| Closed | -$5.94M | – | 323 |
|
|
2017
Q3 | $5.94M | Buy |
+50,588
| New | +$5.94M | 0.64% | 33 |
|
|
2017
Q1 | – | Sell |
-86,245
| Closed | -$3.23M | – | 350 |
|
|
2016
Q4 | $3.23M | Buy |
+86,245
| New | +$3.23M | 0.5% | 33 |
|
|
2015
Q2 | – | Sell |
-58,889
| Closed | -$6.15M | – | 519 |
|
|
2015
Q1 | $6.15M | Buy |
+58,889
| New | +$6.15M | 0.85% | 26 |
|